Kimberly Hicks 8/13/25 Kimberly Hicks 8/13/25 argenx Delivers Strong First Half Performance! Read More Kimberly Hicks 8/11/25 Kimberly Hicks 8/11/25 Alnylam Pharmceuticals continues to lead in RNAi theraputics with a standout quarter! Read More Kimberly Hicks 8/5/25 Kimberly Hicks 8/5/25 Apellis Pharmaceuticals receives FDA approval of EMPAVELI® (pegcetacoplan) Read More Kimberly Hicks 8/4/25 Kimberly Hicks 8/4/25 Congratulations to Dr. Pushkal Garg on his appointment as EVP, Chief Research & Development Officer at Alnylam Pharmaceuticals. Read More Kimberly Hicks 6/13/25 Kimberly Hicks 6/13/25 Meeting the Moment: Supporting Biotech Hiring in a Surplus Market Read More Kimberly Hicks 5/20/25 Kimberly Hicks 5/20/25 argenx Kicks Off 2025 with Record-Breaking Growth Read More Kimberly Hicks 5/10/25 Kimberly Hicks 5/10/25 Big Moves in AI-Driven Oncology: Pathos Secures Major Backing Read More Kimberly Hicks 5/9/25 Kimberly Hicks 5/9/25 Another strong quarter for our client Alnylam Pharmaceuticals Read More Kimberly Hicks 3/24/25 Kimberly Hicks 3/24/25 Pathos has officially dosed the first patient in its Phase 1b/2a clinical trial evaluating Pocenbrodib. Read More Kimberly Hicks 3/21/25 Kimberly Hicks 3/21/25 Congratulations to Alnylam Pharmaceuticals on the FDA Approval of Amvuttra. Read More Kimberly Hicks 3/19/25 Kimberly Hicks 3/19/25 GSS Shares 2024 Year in Review Read More Kimberly Hicks 2/19/25 Kimberly Hicks 2/19/25 Dewpoint Therapeutics succeeds in the nomination of DPTX3496 as their second development candidate! Read More Kimberly Hicks 11/14/24 Kimberly Hicks 11/14/24 Exciting news! Our client, Dewpoint Therapeutics, has been recognized as “One to Watch” by The Pharma Letter. Read More Kimberly Hicks 11/4/24 Kimberly Hicks 11/4/24 Our client, Alnylam Pharmaceuticals submits a sNDA to the FDA Read More Kimberly Hicks 11/1/24 Kimberly Hicks 11/1/24 We’re thrilled to celebrate our client, Pathos, as they expand their pipeline. Read More Kimberly Hicks 9/9/24 Kimberly Hicks 9/9/24 GSS Shares First Half 2024 Placements It all begins with an idea. Read More Kimberly Hicks 9/6/24 Kimberly Hicks 9/6/24 Congratulations to Dewpoint Therapeutics It all begins with an idea. Read More Kimberly Hicks 8/19/24 Kimberly Hicks 8/19/24 Congratulations to PepGen It all begins with an idea. Read More Kimberly Hicks 8/12/24 Kimberly Hicks 8/12/24 Congratulations to CSL Behring It all begins with an idea. Read More Kimberly Hicks 8/6/24 Kimberly Hicks 8/6/24 GSS shares Summary Report It all begins with an idea. Read More Older Posts
Kimberly Hicks 8/13/25 Kimberly Hicks 8/13/25 argenx Delivers Strong First Half Performance! Read More
Kimberly Hicks 8/11/25 Kimberly Hicks 8/11/25 Alnylam Pharmceuticals continues to lead in RNAi theraputics with a standout quarter! Read More
Kimberly Hicks 8/5/25 Kimberly Hicks 8/5/25 Apellis Pharmaceuticals receives FDA approval of EMPAVELI® (pegcetacoplan) Read More
Kimberly Hicks 8/4/25 Kimberly Hicks 8/4/25 Congratulations to Dr. Pushkal Garg on his appointment as EVP, Chief Research & Development Officer at Alnylam Pharmaceuticals. Read More
Kimberly Hicks 6/13/25 Kimberly Hicks 6/13/25 Meeting the Moment: Supporting Biotech Hiring in a Surplus Market Read More
Kimberly Hicks 5/20/25 Kimberly Hicks 5/20/25 argenx Kicks Off 2025 with Record-Breaking Growth Read More
Kimberly Hicks 5/10/25 Kimberly Hicks 5/10/25 Big Moves in AI-Driven Oncology: Pathos Secures Major Backing Read More
Kimberly Hicks 5/9/25 Kimberly Hicks 5/9/25 Another strong quarter for our client Alnylam Pharmaceuticals Read More
Kimberly Hicks 3/24/25 Kimberly Hicks 3/24/25 Pathos has officially dosed the first patient in its Phase 1b/2a clinical trial evaluating Pocenbrodib. Read More
Kimberly Hicks 3/21/25 Kimberly Hicks 3/21/25 Congratulations to Alnylam Pharmaceuticals on the FDA Approval of Amvuttra. Read More
Kimberly Hicks 2/19/25 Kimberly Hicks 2/19/25 Dewpoint Therapeutics succeeds in the nomination of DPTX3496 as their second development candidate! Read More
Kimberly Hicks 11/14/24 Kimberly Hicks 11/14/24 Exciting news! Our client, Dewpoint Therapeutics, has been recognized as “One to Watch” by The Pharma Letter. Read More
Kimberly Hicks 11/4/24 Kimberly Hicks 11/4/24 Our client, Alnylam Pharmaceuticals submits a sNDA to the FDA Read More
Kimberly Hicks 11/1/24 Kimberly Hicks 11/1/24 We’re thrilled to celebrate our client, Pathos, as they expand their pipeline. Read More
Kimberly Hicks 9/9/24 Kimberly Hicks 9/9/24 GSS Shares First Half 2024 Placements It all begins with an idea. Read More
Kimberly Hicks 9/6/24 Kimberly Hicks 9/6/24 Congratulations to Dewpoint Therapeutics It all begins with an idea. Read More
Kimberly Hicks 8/19/24 Kimberly Hicks 8/19/24 Congratulations to PepGen It all begins with an idea. Read More
Kimberly Hicks 8/12/24 Kimberly Hicks 8/12/24 Congratulations to CSL Behring It all begins with an idea. Read More
Kimberly Hicks 8/6/24 Kimberly Hicks 8/6/24 GSS shares Summary Report It all begins with an idea. Read More
